Profound Medical Corp. (PROF)
undefined
undefined%
At close: undefined
7.40
0.14%
After-hours Dec 13, 2024, 03:59 PM EST

Company Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities.

The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids.

Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Corp.
Profound Medical Corp. logo
Country CA
IPO Date Oct 29, 2019
Industry Medical - Devices
Sector Healthcare
Employees 131
CEO Dr. Arun Swarup Menawat MBA, Ph.D.

Contact Details

Address:
2400 Skymark Avenue
Mississauga, ON
CA
Website https://www.profoundmedical.com

Stock Details

Ticker Symbol PROF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001628808
CUSIP Number 74319B502
ISIN Number CA74319B5027
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Dr. Arun Swarup Menawat MBA, Ph.D. Chairman of the Board & Chief Executive Officer
Rashed Dewan Chief Financial Officer
Dr. Mathieu Burtnyk Ph.D. President
Levant Tinaz Software Developer
Matthew Sobczyk C.A., CPA Assistant Corporate Controller
Stephen Kilmer Investor Relations
Thomas Tamberrino MBA Chief Commercial Officer

Latest SEC Filings

Date Type Title
Dec 11, 2024 6-K Filing
Dec 06, 2024 6-K Filing
Dec 06, 2024 SUPPL Filing
Dec 06, 2024 6-K Filing
Dec 05, 2024 6-K Filing
Dec 05, 2024 SUPPL Filing
Dec 05, 2024 6-K Filing
Dec 02, 2024 6-K Filing
Nov 26, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...